$GILD Company News Seven health stocks with buy signals

New Post Public Reply Private Reply Replies (0) Message Board

Dec 19, 2014 at 10:48 AM

$GILD Company News

Seven health stocks with buy signals 10:21 a.m. Dec. 11, 2014 - The Trading Deck
Newscast: Oil called the tune on Wall St. 4:21 p.m. Dec. 10, 2014 - MarketWatch
Cypress, Spansion shares rally on merger plan 5:36 p.m. Dec. 1, 2014 - MarketWatch
Mylan to manufacture, distribute Gilead Sciences HIV drug 7:49 a.m. Dec. 1, 2014 - Angela Chen
10 stocks that may revisit their highs as the year ends 10:30 a.m. Nov. 24, 2014 - Philip van Doorn
Are consumers getting gouged on health care? 9:35 a.m. Nov. 22, 2014 - Russ Britt
Gilead Sciences shares slide 1.7% 9:35 a.m. Nov. 19, 2014 - Sue Chang
The double-edged sword of growth-stock speculation 2:29 p.m. Nov. 14, 2014 - The Trading Deck
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Nov. 11, 2014 - Philip van Doorn
Merck, Dendreon miss out on health-care rally 12:39 p.m. Nov. 10, 2014 - Russ Britt
Gilead Sciences rises 2% to top S&P 500 gainers 9:31 a.m. Nov. 10, 2014 - Sue Chang
Visa shares rise after hours on earnings beat 6:50 p.m. Oct. 29, 2014 - Sue Chang
Warren Buffett best wear his trunks as Fed preps to end (pause) the printing 8:34 a.m. Oct. 29, 2014 - Shawn Langlois
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Updates, advisories and surprises 5:01 p.m. Oct. 28, 2014 - MarketWatch
Sales of Gilead's pricey hepatitis C drug slow 4:26 p.m. Oct. 28, 2014 - MarketWatch.com
Gilead Sciences' stock pulls back from record high close after earnings miss 4:14 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead's stock drops 3.6% in after-hours trade after Q3 results 4:09 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead revises 2014 product sales outlook to $22 bln-$23 bln from $21 bln-$23 bln 4:08 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 Sovaldi sales $2.8 bln vs. $3.48 bln in Q2 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore

The 2015 Calendar Of NASH Trial Catalysts IV: GENFIT And Gilead 8:28 a.m. Today - Seeking Alpha
Update: News On Gilead From The California Technology Assessment Forum 5:45 a.m. Today - Seeking Alpha
Lawsuit Alleges Price Gouging by Maker of Hepatitis Drug 10:50 p.m. Dec. 18, 2014 - The Wall Street Journal Interactive Edition
Jim Cramer's 'Mad Money' Recap: 10 Reasons We'll Have a Santa Claus Rally 8:10 p.m. Dec. 18, 2014 - TheStreet.com
Alexion's Rare Disease Model Analyzed 3:23 p.m. Dec. 18, 2014 - Seeking Alpha
Biogen Idec Poised To Continue Its Stellar Run 12:46 p.m. Dec. 18, 2014 - Seeking Alpha
Is it Time to Sell Gilead Sciences? 10:27 a.m. Dec. 18, 2014 - GuruFocus.com
Chimerix and ContraVir team up in antiviral development 10:23 a.m. Dec. 18, 2014 - Seeking Alpha
2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses 9:35 a.m. Dec. 18, 2014 - TheStreet.com
Ho Ho Harvoni: Gilead Sciences Is A Gift That Should Be Under Every Investor's Tree. 7:36 a.m. Dec. 18, 2014 - Seeking Alpha
AbbVie Pins Hopes on Hepatitis C Treatment 7:52 p.m. Dec. 17, 2014 - The Wall Street Journal Interactive Edition
A 'Wisdom Of Experts' Portfolio 12:15 p.m. Dec. 17, 2014 - Seeking Alpha
2015 Biotech Drug/Stock Outlook: Here's What You Need to Know 9:20 a.m. Dec. 17, 2014 - TheStreet.com
Gilead Sciences Stands Alone 7:44 a.m. Dec. 17, 2014 - Seeking Alpha
Examining Gilead Sciences' Future Pipeline 7:37 a.m. Dec. 17, 2014 - Seeking Alpha
Meet 5 Big Tech Stocks Expected To See Profits Surge 8:03 p.m. Dec. 16, 2014 - Investors Business Daily
Assessing Gilead's Reality-Perception Gap 11:52 a.m. Dec. 16, 2014 - Seeking Alpha
4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst Blog 11:26 a.m. Dec. 16, 2014 - Zacks.com
How To Beat The Market - My Best Large-Cap Stock Portfolio: Gilead Sciences 10:04 a.m. Dec. 16, 2014 - Seeking Alpha
2015 Healthcare Sector Predictions 6:50 a.m. Dec. 16, 2014 - Seeking Alpha

Reveal Earnings Forecast for Apple, Halliburton, American Realty Capital Properties, Gilead Sciences, Zynga, and Bank of America 8:45 a.m. Dec. 16, 2014 - PR Newswire - PRF
Philippe C. Bishop, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutics 8:30 a.m. Dec. 15, 2014 - BusinessWire - BZX
Critical Alerts For Abercrombie & Fitch, Whole Foods Market, Gilead Sciences, JC Penney and Activision Blizzard Released By InvestorsObserver 9:31 a.m. Dec. 10, 2014 - PR Newswire - PRF
Class Action Lawsuit Challenges the Exorbitant Pricing of Gilead's Hepatitis-C Drug Sovaldi 6:39 p.m. Dec. 9, 2014 - PR Newswire - PRF
BetterInvesting Magazine Releases February Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use 4:43 p.m. Dec. 9, 2014 - PR Newswire - PRF
Biogen Idec and Gilead Sciences Join the National Pharmaceutical Council 9:15 a.m. Dec. 9, 2014 - PR Newswire - PRF
Gilead Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 10:00 a.m. Dec. 8, 2014 - BusinessWire - BZX
Reveal Earnings Forecast for Gilead Sciences, Apple, Transocean, Halliburton, Ctrip, and Sirius XM 8:45 a.m. Dec. 8, 2014 - PR Newswire - PRF
Reveal Earnings Forecast for Gilead Sciences, Kinder Morgan, JD.Com, Sirius XM, Apple, and Plug Power 8:45 a.m. Dec. 4, 2014 - PR Newswire - PRF
Earnings Forecast Reports for Apple, Alibaba, Kinder Morgan, Gilead Sciences, Plug Power, and Yahoo 8:45 a.m. Dec. 2, 2014 - PR Newswire - PRF
Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)-based HIV Treatments in Developing Countries 7:00 a.m. Dec. 1, 2014 - PR Newswire - PRF
Reveal Earnings Forecast for Apple, Alibaba, Hewlett-Packard, Gilead Sciences, Petrobras, and BlackBerry 8:45 a.m. Nov. 26, 2014 - PR Newswire - PRF
Critical Alerts For SouFun, Petroleo Brasileiro, Gilead Sciences, Transocean and iRobot Released By InvestorsObserver 9:31 a.m. Nov. 24, 2014 - PR Newswire - PRF
Earnings Forecast Research for Kinder Morgan, Petrobras, Freeport-McMoRan, Keurig Green Mountain, Gilead Sciences, and Alibaba 8:45 a.m. Nov. 24, 2014 - PR Newswire - PRF
Earnings Forecast Report for Yahoo, Alibaba, Cliffs Natural Resources, Gilead Sciences, Apple, and Plug Power 8:45 a.m. Nov. 20, 2014 - PR Newswire - PRF
Knight Sells Priority Review Voucher to Gilead 5:11 p.m. Nov. 19, 2014 - Marketwired
European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4 10:07 a.m. Nov. 18, 2014 - BusinessWire - BZX
Earnings Forecast Buzz for Baker Hughes, Halliburton, Apple, Gilead Sciences, Kinder Morgan, and Alibaba 8:45 a.m. Nov. 18, 2014 - PR Newswire - PRF
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Reveal Earnings Forecast for BlackBerry, Twitter, Alibaba, Sirius XM, Gilead Sciences, and JD.Com 8:45 a.m. Nov. 14, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...